BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27464947)

  • 1. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.
    Yamazaki H; Suemizu H; Kazuki Y; Oofusa K; Kuribayashi S; Shimizu M; Ninomiya S; Horie T; Shibata N; Guengerich FP
    Chem Res Toxicol; 2016 Aug; 29(8):1279-81. PubMed ID: 27464947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry.
    Yamazaki H; Kuribayashi S; Inoue T; Tateno C; Nishikura Y; Oofusa K; Harada D; Naito S; Horie T; Ohta S
    Chem Res Toxicol; 2010 Jan; 23(1):152-8. PubMed ID: 19928966
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Uehara S; Murayama N; Higuchi Y; Shimizu M; Suemizu H; Guengerich FP; Yamazaki H
    Chem Res Toxicol; 2024 May; 37(5):671-674. PubMed ID: 38626399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.
    Yamazaki H; Suemizu H; Shimizu M; Igaya S; Shibata N; Nakamura M; Chowdhury G; Guengerich FP
    Chem Res Toxicol; 2012 Feb; 25(2):274-6. PubMed ID: 22268628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes.
    Miura T; Uehara S; Shimizu M; Suemizu H; Yamazaki H
    J Toxicol Sci; 2021; 46(7):311-317. PubMed ID: 34193768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.
    Yamazaki H; Suemizu H; Mitsui M; Shimizu M; Guengerich FP
    Chem Res Toxicol; 2016 Dec; 29(12):1903-1911. PubMed ID: 27337115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity.
    Murayama N; Kazuki Y; Satoh D; Arata K; Harada T; Shibata N; Guengerich FP; Yamazaki H
    J Toxicol Sci; 2017; 42(3):343-348. PubMed ID: 28496040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.
    Chowdhury G; Shibata N; Yamazaki H; Guengerich FP
    Chem Res Toxicol; 2014 Jan; 27(1):147-56. PubMed ID: 24350712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice.
    Nishiyama S; Suemizu H; Shibata N; Guengerich FP; Yamazaki H
    Chem Res Toxicol; 2015 Nov; 28(11):2088-90. PubMed ID: 26492539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.
    Shimizu M; Suemizu H; Mitsui M; Shibata N; Guengerich FP; Yamazaki H
    Xenobiotica; 2017 Oct; 47(10):844-848. PubMed ID: 27852146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS.
    Ohtsuki S; Kawakami H; Inoue T; Nakamura K; Tateno C; Katsukura Y; Obuchi W; Uchida Y; Kamiie J; Horie T; Terasaki T
    Drug Metab Dispos; 2014 Jun; 42(6):1039-43. PubMed ID: 24711249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice.
    Yamazaki H; Suemizu H; Murayama N; Utoh M; Shibata N; Nakamura M; Guengerich FP
    Chem Res Toxicol; 2013 Mar; 26(3):486-9. PubMed ID: 23419139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5'-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species.
    Kuwagata M; Hasegawa T; Takashima H; Shimizu M; Kitajima S; Yamazaki H
    J Toxicol Sci; 2021; 46(12):553-560. PubMed ID: 34853241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.
    Yamazaki H; Suemizu H; Igaya S; Shimizu M; Shibata N; Nakamura M; Chowdhury G; Guengerich FP
    Chem Res Toxicol; 2011 Mar; 24(3):287-9. PubMed ID: 21299192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes.
    Yamazaki H; Shimizu M
    Drug Metab Dispos; 2023 Jan; 51(1):123-129. PubMed ID: 35772770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of human cytochromes P450 in chimeric mice with humanized liver.
    Katoh M; Matsui T; Nakajima M; Tateno C; Kataoka M; Soeno Y; Horie T; Iwasaki K; Yoshizato K; Yokoi T
    Drug Metab Dispos; 2004 Dec; 32(12):1402-10. PubMed ID: 15383493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Viability and differentiation of human hepatocytes immunoprotected by macroencapsulation and transplanted in rats].
    Nicoluzzi JE; Barbu V; Baudrimont M; Lakehal F; Becquemont L; Chafaï N; Delelo R; Sarkis R; Honiger J; Housset C; Balladur P
    Gastroenterol Clin Biol; 2000 Mar; 24(3):342-8. PubMed ID: 10804344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric mice with humanized liver.
    Katoh M; Tateno C; Yoshizato K; Yokoi T
    Toxicology; 2008 Apr; 246(1):9-17. PubMed ID: 18248870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells.
    Reilly CA; Ehlhardt WJ; Jackson DA; Kulanthaivel P; Mutlib AE; Espina RJ; Moody DE; Crouch DJ; Yost GS
    Chem Res Toxicol; 2003 Mar; 16(3):336-49. PubMed ID: 12641434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
    Yamazaki H
    Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.